{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:32:36Z","timestamp":1781976756400,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Eisai Inc."},{"name":"management, analysis and interpretation of the data"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.seizure.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T11:48:05Z","timestamp":1591616885000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy"],"prefix":"10.1016","volume":"80","author":[{"given":"Christian","family":"Brandt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-8284","authenticated-orcid":false,"given":"Manoj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-1367","authenticated-orcid":false,"given":"Leock Y.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J.","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2020.06.011_bib0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","year":"1989","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2020.06.011_bib0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","author":"International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2020.06.011_bib0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/14656566.2014.915029","article-title":"Pharmacotherapy for tonic-clonic seizures","volume":"15","author":"Rheims","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2020.06.011_bib0020","article-title":"The epilepsies: seizures, syndromes and management","author":"CP., P","year":"2005","journal-title":"Idiopathic Generalised Epilepsies. In: Bladon Medical Publishing"},{"issue":"1","key":"10.1016\/j.seizure.2020.06.011_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1157.1998.tb01268.x","article-title":"Antiepileptic drugs as a cause of worsening seizures","volume":"39","author":"Perucca","year":"1998","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2020.06.011_bib0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.braindev.2011.05.001","article-title":"Worsening of negative myoclonus by lamotrigine in a case of idiopathic focal epilepsy of children with long-term follow-up","volume":"34","author":"Gelisse","year":"2012","journal-title":"Brain Dev"},{"issue":"Pt 5","key":"10.1016\/j.seizure.2020.06.011_bib0035","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/brain\/awl047","article-title":"Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy","volume":"129","author":"Thomas","year":"2006","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.seizure.2020.06.011_bib0040","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.0013-9580.2004.19704.x","article-title":"Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies","volume":"45","author":"Gelisse","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.06.011_bib0045","series-title":"Tegretol\u00ae and tegretol\u00ae-XR prescribing information","author":"Food and Drug Administration (FDA)","year":"2018"},{"key":"10.1016\/j.seizure.2020.06.011_bib0050","series-title":"Dilantin\u00ae extended capsules prescribing information","author":"Food and Drug Administration","year":"2017"},{"issue":"10","key":"10.1016\/j.seizure.2020.06.011_bib0055","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00415-002-0857-3","article-title":"Non convulsive status epilepticus after replacement of valproate with lamotrigine","volume":"249","author":"Trinka","year":"2002","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2020.06.011_bib0060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.06.011_bib0065","series-title":"Lamictal\u00ae prescribing information","author":"Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.seizure.2020.06.011_bib0070","series-title":"Fycompa\u00ae prescribing information","author":"Food and Drug Administration (FDA)","year":"2018"},{"key":"10.1016\/j.seizure.2020.06.011_bib0075","series-title":"Fycompa\u00ae annex I: summary of product characteristics","author":"European Medicines Agency (EMA)","year":"2017"},{"issue":"11","key":"10.1016\/j.seizure.2020.06.011_bib0080","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.06.011_bib0085","doi-asserted-by":"crossref","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2020.06.011_bib0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ane.12931","article-title":"Retrospective study of perampanel efficacy and tolerability in myoclonic seizures","volume":"138","author":"Gil-Lopez","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2020.06.011_bib0095","first-page":"S42","article-title":"Preliminary open-label experience with topiramate in primary generalized seizures","volume":"38","author":"Biton","year":"1997","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2020.06.011_bib0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.59.1.79","article-title":"Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?","volume":"59","author":"Somerville","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2020.06.011_bib0105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2020.06.011_bib0110","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1046\/j.1528-1157.2003.62802.x","article-title":"Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy","volume":"44","author":"Leppik","year":"2003","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2020.06.011_bib0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2020.06.011_bib0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.seizure.2020.06.011_bib0125","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:56:21Z","timestamp":1761011781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120301746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":25,"alternative-id":["S1059131120301746"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.06.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}